Bioverativ Announces 2018 Annual Meeting of Stockholders
December 22 2017 - 4:05PM
Business Wire
Bioverativ Inc. (NASDAQ: BIVV), a global biopharmaceutical
company dedicated to transforming the lives of people with rare
blood disorders, announced today that its 2018 Annual Meeting of
Stockholders has been scheduled for April 25, 2018.
Additional information concerning the 2018 Annual Meeting will
be included in Bioverativ’s 2018 Annual Meeting proxy statement,
which will be filed with the SEC and mailed to Bioverativ’s
stockholders at a later date. Stockholders intending to present a
proposal or nomination for director at the 2018 Annual Meeting,
whether or not for inclusion in the Bioverativ’s proxy materials,
must follow the procedures and timelines set forth in the company's
bylaws and applicable SEC rules.
About BioverativBioverativ is a global biopharmaceutical
company dedicated to transforming the lives of people with
hemophilia and other rare blood disorders through world-class
research, development and commercialization of innovative
therapies. Launched in 2017 following separation from Biogen Inc.,
Bioverativ builds upon a strong heritage of scientific innovation
and is committed to actively working with the blood disorders
community. The company’s mission is to create progress for patients
where they need it most and its hemophilia therapies when launched
represented the first major advancements in hemophilia treatment in
approximately two decades. For more information, visit
bioverativ.com or follow @bioverativ on Twitter.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171222005444/en/
BioverativMEDIA CONTACT:Tracy Vineis, +1
781-663-4350media@bioverativ.comorINVESTOR CONTACT:Samuel Chase, +1
781-663-4360IR@bioverativ.com
Bioverativ Inc. (NASDAQ:BIVV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bioverativ Inc. (NASDAQ:BIVV)
Historical Stock Chart
From Jul 2023 to Jul 2024